research use only

Pegcetacoplan acetate

Cat.No.P1269

Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular haemolysis) and downstream MAC formation (intravascular haemolysis).

Amino-acid Sequence

CAS No. 2019171-69-6

Quality Control

Batch: Purity: 98.06%

98.06

Chemical Information & Solubility

Storage (from the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
			1 month-20°Cin solvent

In vitro
Batch:

DMSO : 100 mg/mL ；
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : 100 mg/mL

Molecular Weight Calculator

In Vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Biological Activity

Description	Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular haemolysis) and downstream MAC formation (intravascular haemolysis).

References
https://pubmed.ncbi.nlm.nih.gov/36459381/

References

https://pubmed.ncbi.nlm.nih.gov/36459381/

Product Information

Molecular Formula	(C₂H₄O)_nC₁₇₀H₂₄₈N₅₀O₄₇S₄
CAS No.	2019171-69-6
Shipping	Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)